



General Assembly

Amendment

January Session, 2015

LCO No. 7616



Offered by:

SEN. HARTLEY, 15th Dist.
REP. PERONE, 137th Dist.
SEN. FRANTZ, 36th Dist.

SEN. CRISCO, 17th Dist.
REP. CAMILLO, 151st Dist.
REP. VARGAS, 6th Dist.

To: Subst. Senate Bill No. 957

File No. 212

Cal. No. 171

**"AN ACT CONCERNING REVISIONS TO THE REGENERATIVE
MEDICINE RESEARCH FUND AND THE CONNECTICUT
BIOSCIENCE INNOVATION FUND, AND THE CONSOLIDATION OF
CERTAIN FUNDS OF CONNECTICUT INNOVATIONS,
INCORPORATED."**

-
- 1 In line 70, strike "the peer review panel"
 - 2 Strike lines 71 and 72 in their entirety and insert the following in
 - 3 lieu thereof: "peer reviewers pursuant to section 32-41mm, as amended
 - 4 by this act."
 - 5 In line 192, before "the" insert an opening bracket
 - 6 In line 193, after "established" insert a closing bracket and after the
 - 7 closing bracket insert "peer reviewers"
 - 8 Strike section 4 in its entirety and insert the following in lieu thereof:

9 "Sec. 4. Section 32-41mm of the general statutes is repealed and the
10 following is substituted in lieu thereof (*Effective July 1, 2015*):

11 [(a) (1) There is established a Regenerative Medicine Research Peer
12 Review Committee. Said peer review committee shall consist of five
13 members.

14 (2) On and before September 30, 2014, all members appointed by the
15 Commissioner of Public Health to the committee shall (A) have
16 demonstrated knowledge and understanding of the ethical and
17 medical implications of regenerative medicine research or related
18 research fields, including, but not limited to, embryology, genetics or
19 cellular biology, (B) have practical research experience in regenerative
20 medicine research or related research fields, including, but not limited
21 to, embryology, genetics or cellular biology, and (C) work to advance
22 regenerative medicine research. Members shall serve for a term of four
23 years commencing on October first, except that three members first
24 appointed by the Commissioner of Public Health shall serve for a term
25 of two years. No member may serve for more than two consecutive
26 four-year terms and no member may serve concurrently on the
27 Regenerative Medicine Research Advisory Committee established
28 pursuant to section 32-41*ll*. All initial appointments to said peer review
29 committee shall be made by October 1, 2005. Any member who fails to
30 attend three consecutive meetings or who fails to attend fifty per cent
31 of all meetings held during any calendar year shall be deemed to have
32 resigned from said peer review committee.

33 (3) On and after October 1, 2014, each member appointed by the
34 Commissioner of Public Health pursuant to subdivision (2) of this
35 subsection may serve to the conclusion of his or her current term at
36 which time members shall be appointed by the chief executive officer
37 of Connecticut Innovations, Incorporated, as follows: Members
38 appointed to said peer review committee shall: (A) Have demonstrated
39 knowledge and understanding of the ethical and medical implications
40 of regenerative medicine research or research in a related field,
41 including, but not limited to, embryology, genetics or cellular biology;

42 (B) have practical research experience in regenerative medicine
43 research or research in a related field, including, but not limited to,
44 embryology, genetics or cellular biology; and (C) work to advance
45 regenerative medicine research. Members shall serve for a term of four
46 years, except that three members first appointed by the chief executive
47 officer of Connecticut Innovations, Incorporated, shall serve for a term
48 of two years. No member may serve for more than two consecutive
49 four-year terms and no member may serve concurrently on the
50 Regenerative Medicine Research Advisory Committee established
51 pursuant to section 32-41ll. Any member who fails to attend three
52 consecutive meetings or who fails to attend fifty per cent of all
53 meetings held during any calendar year shall be deemed to have
54 resigned from said peer review committee.

55 (b) All members shall be deemed public officials and shall adhere to
56 the code of ethics for public officials set forth in chapter 10. No
57 member shall participate in the affairs of the committee with respect to
58 the review or consideration of any grant-in-aid application filed by
59 such member or by any eligible institution in which such member has
60 a financial interest, or with which such member engages in any
61 business, employment, transaction or professional activity.

62 (c) Prior to the awarding of any grants-in-aid for regenerative
63 medicine research pursuant to section 32-41kk, the Regenerative
64 Medicine Research Peer Review Committee shall review all
65 applications submitted by eligible institutions for such grants-in-aid
66 and make recommendations to the Regenerative Medicine Research
67 Advisory Committee established pursuant to section 32-41ll with
68 respect to the ethical and scientific merit of each application.]

69 (a) Prior to the awarding of any financial assistance in response to
70 an application submitted pursuant to section 32-41kk, as amended by
71 this act, the Regenerative Medicine Research Advisory Committee,
72 established pursuant to section 32-41ll, as amended by this act, shall
73 contract with a third party for the selection of peer reviewers to review
74 such application and make recommendations to said advisory

75 committee with respect to the ethical and scientific merit of such
76 application.

77 (b) Such peer reviewers shall: (1) Have a demonstrated knowledge
78 and understanding of the ethical and medical implications of
79 regenerative medicine research or related research fields, including,
80 but not limited to, embryology, genetics or cellular biology; (2) have
81 practical research experience in regenerative medicine research or
82 related research fields, including, but not limited to, embryology,
83 genetics or cellular biology; (3) work to advance regenerative medicine
84 research; and (4) become and remain fully cognizant of the National
85 Academies' Guidelines for Human Embryonic Stem Cell Research, as
86 amended from time to time, and shall utilize said guidelines to
87 evaluate any application pursuant to subsection (a) of this section.

88 (c) No peer reviewer shall review any application filed by such peer
89 reviewer or by any eligible institution in which such peer reviewer has
90 a financial interest, or with which such peer reviewer engages in any
91 business, employment, transaction or professional activity.

92 (d) [Members of the Regenerative Medicine Research Peer Review
93 Committee] Such peer reviewers may receive compensation from
94 Connecticut Innovations, Incorporated, for reviewing [grant-in-aid]
95 applications submitted [by eligible institutions] pursuant to section 32-
96 41kk, as amended by this act. The rate of compensation shall be
97 established by the board of directors of Connecticut Innovations,
98 Incorporated.

99 (e) The Regenerative Medicine Research [Peer Review Committee]
100 Advisory Committee shall establish guidelines for the rating and
101 scoring of such applications. In establishing such guidelines, said
102 advisory committee may consult with a third party contracted for the
103 selection of peer reviewers pursuant to subsection (a) of this section.

104 [(f) All members of said peer review committee shall become and
105 remain fully cognizant of the National Academies' Guidelines for

106 Human Embryonic Stem Cell Research, as amended from time to time,
107 and shall utilize said guidelines to evaluate each grant-in-aid
108 application.]"

109 In line 349, strike ", in the manner therein provided,"

110 In line 350, after "by" insert ", and subject to the same provisions in,"

111 In line 353, after "respectively." insert "The provisions of subsection
112 (c) of section 32-23v of the general statutes shall not apply to the
113 making of such loans."